CymaBay Therapeutics (CBAY) Earns Outperform Rating from Analysts at Raymond James

Stock analysts at Raymond James assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a note issued to investors on Thursday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $20.00 price target on the biopharmaceutical company’s stock. Raymond James’ price target would indicate a potential upside of 49.03% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 12th. Oppenheimer restated a “buy” rating on shares of CymaBay Therapeutics in a research note on Wednesday, March 21st. BidaskClub cut shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. Leerink Swann boosted their target price on shares of CymaBay Therapeutics from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, April 11th. Finally, HC Wainwright initiated coverage on shares of CymaBay Therapeutics in a research note on Wednesday, March 28th. They issued a “buy” rating and a $18.00 target price for the company. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $19.10.

Shares of CymaBay Therapeutics opened at $13.42 on Thursday, according to Marketbeat Ratings. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.91 and a current ratio of 12.91. CymaBay Therapeutics has a 12 month low of $5.10 and a 12 month high of $15.59.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.18). equities research analysts forecast that CymaBay Therapeutics will post -1.18 EPS for the current year.

In other news, CEO Sujal Shah bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 11th. The stock was purchased at an average cost of $10.65 per share, for a total transaction of $53,250.00. Following the purchase, the chief executive officer now directly owns 90,000 shares in the company, valued at approximately $958,500. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.50% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of CBAY. Hillsdale Investment Management Inc. acquired a new position in shares of CymaBay Therapeutics in the 1st quarter valued at $104,000. Schwab Charles Investment Management Inc. purchased a new stake in CymaBay Therapeutics in the 4th quarter worth $115,000. LPL Financial LLC purchased a new stake in CymaBay Therapeutics in the 1st quarter worth $130,000. Quantbot Technologies LP purchased a new stake in CymaBay Therapeutics in the 1st quarter worth $155,000. Finally, Goldman Sachs Group Inc. purchased a new stake in CymaBay Therapeutics in the 4th quarter worth $197,000. Hedge funds and other institutional investors own 82.35% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply